COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network.
Saved in:
| Title: | COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network. |
|---|---|
| Authors: | Laniece Delaunay C; Epiconcept, Paris, France., Verdasca N; Infectious Disease Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal., Monge S; National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain., Domegan L; Health Service Executive, Health Protection Surveillance Centre, Dublin, Ireland., Sève N; Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP), Paris, France., Buda S; Department of Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany., Meijer A; National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, the Netherlands., Lucaccioni H; Epiconcept, Paris, France., López Torrijos M; Subdirección General de Epidemiología y Vigilancia de la Salud, Valencia, Spain., McKenna A; Health Service Executive, Health Protection Surveillance Centre, Dublin, Ireland., Enouf V; Centre National de Référence Virus des Infections Respiratoire (CNR VIR), M3P Unit, Institut Pasteur Université Paris Cité, Paris, France., Dürrwald R; National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany., In't Velt E; National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, the Netherlands., de Valcárcel Laiglesia MÁ; Department of Epidemiology, Regional Health Council, IMIB, Murcia, Spain., Bennett C; National Virus Reference Laboratory, University College, Dublin, Ireland., Masse S; Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France., Erdwiens A; Department of Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany., Hooiveld M; Nivel, Utrecht, the Netherlands., Mlinarić I; Croatian Institute of Public Health, Zagreb, Croatia., Túri G; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary., Rodrigues AP; Epidemiology Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal., Martínez-Baz I; Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain., Lazar M; Cantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania., Latorre-Margalef N; Department of Microbiology, Public Health Agency of Sweden, Stockholm, Sweden., Borges V; Infectious Disease Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal., Kaczmarek M; European Centre for Disease Control and Prevention, Stockholm, Sweden., Bacci S; European Centre for Disease Control and Prevention, Stockholm, Sweden., Kissling E; Epiconcept, Paris, France. |
| Corporate Authors: | European primary care VE group |
| Source: | Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2025 May; Vol. 19 (5), pp. e70120. |
| Publication Type: | Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 101304007 Publication Model: Print Cited Medium: Internet ISSN: 1750-2659 (Electronic) Linking ISSN: 17502640 NLM ISO Abbreviation: Influenza Other Respir Viruses Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1750-2659 |
|---|---|
| DOI: | 10.1111/irv.70120 |
